Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
The company’s androgen receptor degrader might have a pathway to approval, but the potential market looks small.
But the pace of biopharma asset deals dips. Are the two trends related?
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
The French group was to have been first to report key Serd data this year, but has suffered delays as Roche and now Radius beat it to the punch.
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.